You are here

High throughput camelid antibody screening as drug discovery platform

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43GM106519-01A1
Agency Tracking Number: R43GM106519
Amount: $218,085.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIGMS
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
271 GREAT VALLEY PARKWAY SUITE 300
MALVERN, PA 19355-1326
United States
DUNS: 962964990
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 HIEP TRAN
 (610) 990-7531
 tran@abzymetx.com
Business Contact
 TRAM VO
Phone: (610) 990-7531
Email: vo@abzymetx.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Monoclonal antibodies are used for treatment of a wide range of diseases from cancer to infectious diseases. However, development of antibodies with high affinity and specificity is still time-consuming, labor-intensiveand unpredictable. Abzyme Therapeutics LLC is actively developing animal-free antibody discovery platforms to accelerate generation of therapeutic antibodies. In Phase I, we will create a so-called Self-Diversifying Antibody Library or SDALib as a monoclonal antibody generating system that will provide a diverse array of complete antibodies in vitro, without using immunization. The main feature of the system is the ability to self-generate a cell library with diversified antibodies by means of hypermutation induction in antibody encoding genes. Using the SDALib system, generation time of monoclonal antibodies against any antigen will be reduced to about two weeks as compared to 6 to 9 months normally required using conventional techniques. The platfor

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government